News/ News/ Oncology Amgen faces first Neulasta biosimilar rival as FDA approves Mylan drug Dominic Tyer Biocon, biosimilars, fda, Fulphila, Mylan, Neulasta, pegfilgrastim 0 Comment Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar Share X Amgen faces first Neulasta biosimilar rival as FDA approves Mylan drug https://pharmaphorum.com/news/amgen-neulasta-biosimilar-fda-mylan-fulphila/